Emory University v Biochem Pharma Inc

The matter of Emory University v Biochem Pharma Inc was heard before Lindgren J in the Federal Court of Australia, where the dispute centred on intellectual property rights and patent infringement. Emory University, the applicant, sought to enforce its patent rights against various pharmaceutical companies, including Biochem Pharma Inc, the first respondent. The proceedings involved complex issues of patent validity and infringement, particularly concerning a patent related to the use of certain drugs.

The court was tasked with resolving several critical legal issues, including the appropriate service of documents on foreign entities, the validity of the patent in question, and the proper identification of parties involved in the infringement. The court had to determine whether the original service on the second respondent was valid and whether the inclusion of Glaxo Group Limited as a respondent was appropriate. Additionally, the court had to consider whether Emory University should be permitted to amend its application and statement of claim to reflect these changes.

In delivering the judgment, Lindgren J concluded that the original service on the second respondent was ineffective, necessitating its removal from the proceeding. The court also determined that Glaxo Group Limited should be included as a respondent due to its involvement in the patent infringement. The judge further allowed Emory University to amend its application and statement of claim to reflect these changes, as well as granting leave to serve the necessary documents on Glaxo Group Limited outside the Commonwealth. Furthermore, the first respondent was permitted to amend its defence in line with these orders.

The court's orders included setting aside the service on the second respondent, removing the second and third respondents from the proceeding, adding Glaxo Group Limited as a respondent, and granting leave for the necessary amendments and service of documents. The proceeding was stood over to allow for the exchange of written submissions on costs, with a final hearing scheduled to address the cost implications of the case.